雅虎香港 搜尋

搜尋結果

1. medical.eisai.jp › products › mrsメリスロン錠6mg | メリスロン | エーザイ Medical.eisai.jp 医 ...

   medical.eisai.jp › products › mrs

   • 網頁紀錄

   剤形名. メリスロン錠6mgの添付文書、インタビューフォームなどの情報を掲載しています。 エーザイの医療関係者向け情報サイトです。 医療用医薬品を適正にご使用いただくための情報を提供しています。

2. www.eisai.com › news › 2024EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN ...

   www.eisai.com › news › 2024

   • 網頁紀錄

   2024年3月29日 · March 29, 2024. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant Myonal ® (generic name: eperisone hydrochloride) in ...

3. www.kegg.jp › medicus-bin › japic_med医療用医薬品 : メリスロン (メリスロン錠6mg 他) - KEGG

   www.kegg.jp › medicus-bin › japic_med

   • 網頁紀錄

   東京都文京区小石川4-6-10. めまい・平衡障害治療剤; 総称名:メリスロン; 一般名:ベタヒスチンメシル酸塩; 販売名:メリスロン錠6mg, メリスロン錠12mg; 製造会社:エーザイ.

4. www.rad-ar.or.jp › siori › englishMerislon Tablets 6mg | Kusuri-no-Shiori (Drug Information ...

   www.rad-ar.or.jp › siori › english

   Brand name. Merislon Tablets 6mg. Eisai Co., Ltd. Word. 日本語. The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy.

5. www.eisai.com › news › 2022EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL® AND ...

   www.eisai.com › news › 2022

   • 網頁紀錄

   2022年11月7日 · November 7, 2022. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal ® (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) in ...

6. en.acnnewswire.com › press-release › englishEisai to Divest Rights for Merislon and Myonal in Japan to K ...

   en.acnnewswire.com › press-release › english

   • 網頁紀錄

   2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

7. www.asiaone.com › business › eisai-divest-rights-merislon-andEisai to Divest Rights for Merislon and Myonal in Japan to K ...

   www.asiaone.com › business › eisai-divest-rights-merislon-and

   • 網頁紀錄

   2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon®...